Procedure: biospecimen collection    (DrugBank: -)

1 disease
IDDisease name (Link within this page)Number of trials
159Xeroderma pigmentosum1

159. Xeroderma pigmentosum    [ 5 clinical trials,   13 drugs,   (DrugBank: 4 drugs),   4 drug target genes,   13 drug target pathways]
Searched query = "Xeroderma pigmentosum", "XP"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 5 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04500548
(ClinicalTrials.gov)
February 26, 20214/8/2020Testing the Combination of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) in Children, Adolescent, and Young Adult Patients With Relapsed/Refractory Cancers That Have an Increased Number of Genetic Changes, The 3CI Study3CI Study: Childhood Cancer Combination Immunotherapy. Phase Ib and Expansion Study of Nivolumab Combination Immunotherapy in Children, Adolescent, and Young Adult (CAYA) Patients With Relapsed/Refractory Hypermutant CancersConstitutional Mismatch Repair Deficiency Syndrome;Hematopoietic and Lymphoid Cell Neoplasm;Lynch Syndrome;Recurrent Lymphoma;Recurrent Malignant Solid Neoplasm;Recurrent Neuroblastoma;Recurrent Primary Central Nervous System Neoplasm;Refractory Lymphoma;Refractory Malignant Solid Neoplasm;Refractory Neuroblastoma;Refractory Primary Central Nervous System Neoplasm;Xeroderma PigmentosumProcedure: Biospecimen Collection;Biological: Ipilimumab;Biological: NivolumabNational Cancer Institute (NCI)NULLNot yet recruiting12 Months25 YearsAll40Phase 1NULL